LEXINGTON, Mass., Nov. 20,
2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development and
commercialization of innovative therapeutics for the treatment of
cancer, today announced three upcoming poster presentations at the
60th annual meeting of the American Society of
Hematology. Curis's poster presentations will be available for
viewing on Monday, December 3
(Session III) from 10 a.m. to 8 p.m.
PT with presentations from 6 p.m. to
8 p.m. PT in Hall GH at the San
Diego Convention Center.
Curis will present three posters at the ASH conference providing
key information supporting development of fimepinostat in patients
with DLBCL, including patients with MYC-alterations, and CA-4948,
Curis's IRAK4 inhibitor, for patients with lymphomas. A pooled
analysis of R/R DLBCL patients treated with fimepinostat
demonstrates adequate safety and anti-tumor activity supporting the
biologic rationale for continued development of fimepinostat in
this patient population. Additionally, Curis will present
preclinical data and biological rationale that support CA-4948
development in patients with tumors sensitive to the IRAK4
signaling pathway as well as data supporting the potential for
IRAK4-based combination regimens to overcome drug tolerance in
patients with Non-Hodgkin Lymphoma.
Details of these presentations are as follows:
Curis Presentations at American Society of Hematology
60th Annual Meeting
Viewing
Date/Time:
|
Monday, Dec. 3, 10:00
AM – 8:00 PM PT
|
|
|
Presentation
Date/Time:
|
Monday, Dec. 3, 6:00
PM – 8:00 PM PT
|
|
|
Location:
|
Hall GH, San Diego
Convention Center
|
|
|
Abstract
Number:
|
4168
|
|
|
Presentation
Title:
|
Preclinical
Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination
with Targeted Therapies and Preliminary Phase 1 Clinical Results in
Non-Hodgkin Lymphoma
|
|
|
Abstract
Number:
|
4184
|
|
|
Presentation
Title:
|
A Pooled Analysis
of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat
(CUDC-907), Including Patients with MYC-Altered
Disease
|
|
|
Abstract
Number:
|
2649
|
|
|
Presentation
Title:
|
Drug Combinations
Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome
Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin
Lymphomas
|
About Curis, Inc.
Curis is a biotechnology company focused on the development and
commercialization of innovative therapeutics for the treatment of
cancer, including fimepinostat, which is being investigated in
clinical studies in patients with DLBCL and solid tumors. Curis is
also engaged in a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including, the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing
testing in a Phase 1 trial in patients with advanced solid tumors
and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is
currently undergoing testing in a Phase 1 trial in patients with
non-Hodgkin lymphoma. Curis is also party to a collaboration with
Genentech, a member of the Roche Group, under which Genentech and
Roche are commercializing Erivedge® for the treatment of advanced
basal cell carcinoma. For more information, visit Curis's website
at www.curis.com.
View original
content:http://www.prnewswire.com/news-releases/curis-to-present-at-the-60th-annual-meeting-of-the-american-society-of-hematology-300753716.html
SOURCE Curis, Inc.